Cancer antigen 27-29 (CA27-29) is a protein marker that can be used to detect and monitor the progress of certain types of cancer. It is most commonly associated with breast cancer, but it is also found in other cancers such as ovarian, lung, and gastric cancers. In this blog post, we will discuss the causes, symptoms and treatment for CA27-29 as well as how it is used to diagnose different types of cancer. We will also look at the latest research into this protein marker and explore potential new methods for detecting and monitoring the progression of different types of cancer.
Cancer antigen 27-29 (CA27-29) is a tumor marker for breast cancer. CA27-29 is found in the blood of some women with breast cancer. It may be used to help find breast cancer early. CA27-29 may also be used to see how well treatment is working or to check for breast cancer recurrence.
Cancer is a disease caused by the abnormal growth of cells in the body. Cancerous cells can grow and spread to other parts of the body, which can be life-threatening. The cause of cancer is not fully understood, but it is known that cancerous cells develop when there is a change in the genetic material of a cell. This change can be caused by exposure to certain substances, such as tobacco smoke or radiation. It can also be inherited from a person's parents. There are many different types of cancer, each with its own set of causes.
Cancer antigen (CA) 27-29 is a protein that is found on the surface of some cancer cells. It is used as a marker to help diagnose and monitor certain types of cancer. CA 27-29 levels may be elevated in people with breast, ovarian, or pancreatic cancer.
Elevated CA 27-29 levels may be a sign of cancer, but they can also occur in other conditions.
Additional symptoms that may be associated with CA 27-29 elevation include:
• Fatigue
• Weight loss
• Loss of appetite
• Nausea and vomiting
• Pain
• Jaundice (yellowing of the skin)
Cancer antigen (CA) 27-29 is a protein found on the surface of many types of cancer cells. It is used as a marker to help diagnose certain types of cancer, including ovarian cancer and breast cancer. CA 27-29 levels may also be increased in other conditions, such as benign (non-cancerous) tumors and certain inflammatory diseases.
Cancer antigen 27-29 is a protein that is produced by some types of cancer cells. It is used as a marker to help diagnose and monitor certain types of cancer. Cancer antigen 27-29 levels may be higher in people with:
-Lung cancer
-Breast cancer
-Ovarian cancer
-Colorectal cancer
Cancer antigen 27-29 levels can be measured with a blood test. If the levels are high, it may be an indication that the cancer is present or returning. Treatment for cancer usually involves surgery, chemotherapy, and/or radiation therapy.
Cancer antigen 27-29 is a protein that is produced by some types of cancer cells. This protein can be detected in the blood of people with certain types of cancer, such as ovarian cancer. Cancer antigen 27-29 is not a specific marker for any one type of cancer, but it may be useful in detecting early stage ovarian cancer and other cancers. There is no specific treatment for cancer antigen 27-29, but it is important to detect and treat the underlying cancer as soon as possible.
In conclusion, cancer antigen 27-29 is a protein produced by certain types of cancers and can be used as a marker to diagnose the presence of these diseases. With early diagnosis and proper treatment, cancer caused by CA27-29 may have an improved prognosis. We hope this article has provided you with more information about what CA27-29 is, its causes, symptoms and how it can be treated.
1.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
2.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
3.
Recurrent UTIs impact eGFR in children with vesicoureteral reflux
4.
Month-Long Wait Times Caused by US Physician Shortage.
5.
Pharyngoesophageal junction cancer is not a good candidate for endoscopically assisted transoral surgery.
1.
A Closer Look at Poorly Differentiated Carcinoma: Uncovering its Complexities
2.
The Importance of Early Detection in Angiosarcoma: A Story of Survival
3.
Leukemia in Focus: Tools, Trials, and Therapy Strategies for Modern Medical Practice
4.
New Research Advances in the Treatment of Multiple Myeloma and Plasmacytoma
5.
Managing KRAS Inhibitor Toxicities: Focus on Rash and Beyond
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III
4.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion IV
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation